跳至主要内容
临床试验/NL-OMON52830
NL-OMON52830已完成不适用

Interventional, open-label, exploratory study, investigating the safety, tolerability, pharmacokinetics, and efficacy of Lu AF28996 in patients with Parkinson*s disease - CS0334 Lundbeck (18252A)

H. Lundbeck A/S0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - The patient is able to read and understand the Subject Information Sheet and
  • Informed Consent Form.
  • - The patient has signed the study-specific Informed Consent Form.
  • - The patient is diagnosed with idiopathic Parkinson*s disease (consistent with
  • the UK Parkinson*s Disease Society Brain Bank Criteria for the Diagnosis of PD)
  • and should not have more than 1 first-degree relative with PD.
  • - The patient*s Modified Hoehn and Yahr score is *3 in the ON state and *4 in
  • the OFF state.
  • - The patient experiences well recognizable and predictable motor fluctuations
  • (at least 1.5 hours of OFF-periods in the awake time, predictable morning OFF
  • episodes included) causing clinically significant disability during the 7-week
  • Screening Period.

排除标准

  • - The patient has previously been enrolled in this study.
  • - The patient takes or has taken disallowed recent or concomitant medication
  • (specified in Appendix II of the CSP) or it is anticipated that the patient
  • will require treatment with at least one of the disallowed concomitant
  • medications during the study. Patients who have taken any non-prescribed
  • systemic or topical medication may participate in the study if, in the opinion
  • of the investigator, the medication will not interfere with the study
  • procedures, study results, or compromise safety.
  • - The patient is a member of the study personnel or of their immediate
  • families, or is a subordinate (or immediate family member of a subordinate) to
  • any of the study personnel.

研究者

相似试验